Positions the Company as a new leader in providing solutions that bridge the gap between cellular electrophysiology and advanced analysis techniques DURHAM, NORTH CAROLINA, UNITED

ST. LOUIS, March 15, 2023 /PRNewswire/ — Panome Bio, a metabolomics and proteomics services company that provides biopharma innovators unparalleled access into the biomolecules closest

VENLO, The Netherlands & SAN DIEGO–(BUSINESS WIRE)– QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the

Madison, WI USA, January 5, 2023–/BusinessWire/ — Nimble Therapeutics, a biotechnology company leveraging its next-generation peptide discovery platform to identify medicines for challenging-to-drug targets, today

MADISON, WI, USA, December 13, 2022 — Nimble Therapeutics Inc., a leading peptide therapeutics company, today announced they have achieved discovery milestones for two programs

Madison, Wisconsin, November 30th, 2022 – Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific

October 24, 2022 | For Immediate Release Former Healthcare Research Analyst and Investment Banker Expands Firm’s Operational Depth and Sector Expertise San Francisco, California (October

San Francisco, June 30, 2022 – Telegraph Hill Partners (THP), a venture capital and growth equity firm dedicated to building life science and healthcare technology

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced

Boulder, CO: Mosaic Biosciences (“Mosaic” or “the Company”), a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and

MADISON, WI, USA, [05/17/2022] — Nimble Therapeutics Inc. today announced the company has achieved the first development milestone for each of several programs attached to

Marcy l’Étoile, France, April 12th 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an